From: Decoding the usefulness of non-coding RNAs as breast cancer markers
Therapies | Role in response | miRNA | Putative targets | Agent | Biological samples | Refs. |
---|---|---|---|---|---|---|
Hormone therapy | ||||||
Antiestrogens | Sensitivity | miR-342 | CCNB1 | Tamoxifen | Cell lines and tumor tissues | [149] |
miR-26a | EZH2 | Â | Tumor tissues | [150] | ||
miR-30c | EGFR | Â | Â | [147] | ||
miR-10, -126 | – |  |  | [151] | ||
Resistance | miR-221/222 | CDKN1B | Tamoxifen, fulvestrant | Tumor tissues and cell lines | ||
miR-519a | CDKN1B PTEN, RB1 | Tamoxifen | Tumor tissues and cell lines | [154] | ||
miR-155 | SOCS6 | Â | Â | [131] | ||
miR-210 | – |  | Tumor tissues | [110] | ||
miR-301 | FOXF2, BBC3, PTEN, COL2A1 | Â | Tumor tissues, cell lines and xenografts | [94] | ||
Aromatase inhibitors | Sensitivity | miR-125b let-7c | ERBB2 | Letrozole, anastrozole | Tumor tissues and cell lines | [116] |
Resistance | miR-181a | BCL2L11 | Letrozole | Cell lines, xenografts and tumor tissues | [155] | |
Antibodies | Sensitivity | miR-210 | – | Trastuzumab | Cell lines and plasma | [148] |
Resistance | miR-21 | PTEN | Trastuzumab | Cell lines, xenograft and tumor tissues | [156] | |
Chemotherapy | Sensitivity | miR-451 | MRP-1 | Doxorubicin | Cell lines and tumor tissues | [157] |
miR-200c | MRP-1 | Â | Â | [158] | ||
miR-134 | ABCC1 | Â | Â | [159] | ||
miR-128 | BMI1, ABCC5 | Doxorubicin, Paclitaxel | Cell lines, xenografts and tumor tissues | [121] | ||
miR-100 | MTOR | Paclitaxel | Cell lines, xenografts and luminal tumor tissues | [119] | ||
miR-16 | IKBKB | Â | Cell lines and tumor tissues | [160] | ||
miR-621 | FBXO11 | Paclitaxel + Carboplatin | Cell lines, xenografts and tumor tissues | [161] | ||
Resistance | miR-125b | BAK1, E2F3 | FEC | Cell lines, tumor tissues and serum | [162] | |
miR-141 | − | Taxane, Anthracyclines | Cell lines and tumor tissues | [163] | ||
miR-221 | CDKN1B | Â | Plasma | [164] | ||
miR-155 | FOXO3a | Paclitaxel, VP-16, Doxorubicin | Cell lines and tumor tissues | [165] | ||
Radiotherapy | Sensitivity | miR-155 | RAD51 | – | Cell lines and TNBC tissues | [166] |